ArdelyxARDX
About: Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Employees: 395
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
58% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 55
31% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 32
5% more capital invested
Capital invested by funds: $765M [Q4 2024] → $806M (+$41.3M) [Q1 2025]
5.16% more ownership
Funds ownership: 63.69% [Q4 2024] → 68.84% (+5.16%) [Q1 2025]
3% more funds holding
Funds holding: 210 [Q4 2024] → 217 (+7) [Q1 2025]
14% less call options, than puts
Call options by funds: $11.5M | Put options by funds: $13.3M
33% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Matthew Caufield | 123%upside $10 | Buy Assumed | 18 Jun 2025 |
Citigroup Yigal Nochomovitz | 123%upside $10 | Buy Maintained | 2 May 2025 |
Financial journalist opinion
Based on 7 articles about ARDX published over the past 30 days
